N,N’-Bis-boc-1-guanylpyrazole | CAS:152120-54-2

We serve N,N’-Bis-boc-1-guanylpyrazole CAS:152120-54-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
N,N'-Bis-boc-1-guanylpyrazole

Chemical Name:N,N'-Bis-boc-1-guanylpyrazole
CAS.NO:152120-54-2
Synonyms:N,N'-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxa;tert-Butyl [(Boc-amino)(1H-pyrazol-1-yl)methylene]carbamate;Pyrazol(Boc)2
Molecular Formula:C14H22N4O4
Molecular Weight:310.34900
 
Physical and Chemical Properties:
Density:1.16;
Melting point:86-90oC;
Index of Refraction:1.525;
 
HS Code: 2933199090
 
Specification:
Appearance:White powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As a condensation reagent



Contact us for information like N,N’-Bis-boc-1-guanylpyrazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrazol(Boc)2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrazol(Boc)2 Use and application,Pyrazol(Boc)2 technical grade,usp/ep/jp grade.


Related News: TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.Dimethyl 2-(2-Methoxyphenoxy)Malonate manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.1-Bromo-4-chlorobutane supplier With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.[4-(pyrrolidin-1-ylsulfonylmethyl)phenyl]hydrazine,hydrochloride vendor With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.